Christina Wilson

International Stroke Conference attendance for UF Vascular Neurology Fellows

CTOA Wilson

ACGME Back to Bedside Initiative

A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarction in Patients Receiving Aspirin and Clopidogrel Following Acute Ischemic Stroke or Transient Ischemic Attack (TIA)

ARCADIA CSI (Cognition and Silent Infarcts) "Study"

AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke (ARCADIA)

A MULTICENTER DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED PARALLEL GROUP DOSE RANGING STUDY TO EVALUATE THE SAFETY....

AN EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY,TOLERABILITY & EFFICACY OF DALFAMPRIDINE EXTENDED-RELEASE TABLETS...

DALF-PS-1016: A Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Two Dose Strengths of Dalfampridine Extended Release Tablets for Treatment of Stable Walking Deficits in Post-Ischemic Stroke (MILESTONE).

Mltictr, rdmzd,dble-blind,dble-dummy,actve-comparator,event-driven, superiority ph 3I stdy of sec. prevtn. of strke and prevtn of systematic embolism in pts/w a recent Embolic Stroke of Undtrmned Srce ,compring rivaroxaban 15 mg once dly w/aspirin 100 mg